Merit Medical Q2 Earnings Beat Consensus; View Point Acquisition and DualCap Divestiture Reshape Portfolio
MMSI sits 46% above its 52-week low of $59.74 on elevated volume (2.3× avg).
Summary
Merit Medical reported Q2 2026 adjusted EPS of $1.19, beating estimates by 24%, on revenue of $418.8 million. The company completed the View Point Medical acquisition and sold its DualCap product line, reshaping its portfolio.
Key Events · Earnings and Guidance · MMSI
-
Q2 Earnings Beat
Adjusted EPS of $1.19 beat the $0.96 consensus by 24%. Revenue rose 9.5% to $418.8 million, driven by strong therapeutic sales growth of 14.8%.
-
Gross Margin Expansion
Gross margin improved to 51.4% from 48.2% a year ago, aided by a $6.9 million refund of previously paid IEEPA tariffs and favorable product mix.
-
View Point Medical Acquisition Closed
On April 1, 2026, Merit acquired View Point Medical for $90 million upfront plus two $25 million deferred payments, adding the OneMark breast tumor localization system.
-
DualCap Divestiture Completed
The sale of the DualCap product line to Health Line closed on February 17, 2026, generating a $12.5 million pre-tax gain and $25.5 million in cash proceeds.
Analysis · MMSI · Industrial Applications And Services
Merit Medical delivered a strong Q2, with adjusted EPS of $1.19 beating consensus by 24% on revenue of $418.8 million, up 9.5% year-over-year. Gross margin expanded to 51.4% from 48.2%, helped by a $6.9 million tariff refund. The quarter also saw the closing of the View Point Medical acquisition for $90 million upfront, adding breast tumor localization technology, and the divestiture of the DualCap product line for a $12.5 million pre-tax gain. These moves sharpen the portfolio toward higher-growth therapeutic areas. Two executives adopted 10b5-1 trading plans, a routine disclosure but worth noting given the stock's recent strength.
At the time of this filing, MMSI was trading at $87.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5B. The 52-week trading range was $59.74 to $94.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.